[1] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会.  中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.   doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology.  Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol, 2018, 46(10): 760-789.   doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
[2] Seferovic PM, Ponikowski P, Anker SD, et al.  Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(10): 1169-1186.   doi: 10.1002/ejhf.1531
[3] Kjeldsen SE, von Lueder TG, Smiseth OA, et al.  Medical therapies for heart failure with preserved ejection fraction[J]. Hypertension, 2020, 75(1): 23-32.   doi: 10.1161/HYPERTENSIONAHA.119.14057
[4] Zile MR, Gottdiener JS, Hetzel SJ, et al.  Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction[J]. Circulation, 2011, 124(23): 2491-2501.   doi: 10.1161/CIRCULATIONAHA.110.011031
[5] Travin MI.  Cardiac neuronal imaging at the edge of clinical application[J]. Cardiol Clin, 2009, 27(2): 311-327.   doi: 10.1016/j.ccl.2008.12.007
[6] Schwartz PJ, De Ferrari GM.  Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure[J]. Heart Fail Rev, 2011, 16(2): 101-107.   doi: 10.1007/s10741-010-9179-1
[7] Reddy YNV, Carter RE, Obokata M, et al.  A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction[J]. Circulation, 2018, 138(9): 861-870.   doi: 10.1161/CIRCULATIONAHA.118.034646
[8] Pieske B, Tschöpe C, de Boer RA, et al.  How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2020, 22(3): 391-412.   doi: 10.1002/ejhf.1741
[9] Almeida P, Rodrigues J, Lourenço P, et al.  Left atrial volume index is critical for the diagnosis of heart failure with preserved ejection fraction[J]. J Cardiovasc Med (Hagerstown), 2018, 19(6): 304-309.   doi: 10.2459/JCM.0000000000000651
[10]

Singh A, Carvalho Singulane C, Miyoshi T, et al. Normal values of left atrial size and function and the impact of age: results of the world alliance societies of echocardiography study[J]. J Am Soc Echocardiogr, 2022, 35(2): 154−164.e3. DOI: 10.1016/j.echo.2021.08.008.
[11] Ho CY, Solomon SD.  A clinician's guide to tissue Doppler imaging[J]. Circulation, 2006, 113(10): e396-e398.   doi: 10.1161/CIRCULATIONAHA.105.579268
[12] Harada T, Obokata M, Omote K, et al.  Independent and incremental prognostic value of semiquantitative measures of tricuspid regurgitation severity in heart failure with preserved ejection fraction[J]. Eur Heart J Cardiovasc Imaging, 2021, 22(12): 1443-1451.   doi: 10.1093/ehjci/jeaa264
[13] Obokata M, Kane GC, Reddy YNV, et al.  Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study[J]. Circulation, 2017, 135(9): 825-838.   doi: 10.1161/CIRCULATIONAHA.116.024822
[14]

Belyavskiy E, Morris DA, Url-Michitsch M, et al. Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study[J/OL]. ESC Heart Fail, 2019, 6(1): 146−153[2023-02-13]. https://onlinelibrary.wiley.com/doi/10.1002/ehf2.12375. DOI: 10.1002/ehf2.12375.
[15] Donal E, Lund LH, Oger E, et al.  Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study[J]. Eur Heart J Cardiovasc Imaging, 2016, 17(1): 106-113.   doi: 10.1093/ehjci/jev144
[16] Aalen J, Storsten P, Remme EW, et al.  Afterload hypersensitivity in patients with left bundle branch block[J]. JACC Cardiovasc Imaging, 2019, 12(6): 967-977.   doi: 10.1016/j.jcmg.2017.11.025
[17]

Lee JH, Park JH. Role of echocardiography in clinical hypertension[J/OL]. Clin Hypertens, 2015, 21: 9[2023-02-13]. https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-015-0015-8. DOI: 10.1186/s40885-015-0015-8.
[18]

Park JJ, Mebazaa A, Hwang IC, et al. Phenotyping heart failure according to the longitudinal ejection fraction change: myocardial strain, predictors, and outcomes[J/OL]. J Am Heart Assoc, 2020, 9(12): e015009[2023-02-13]. https://www.ahajournals.org/doi/10.1161/JAHA.119.015009. DOI: 10.1161/JAHA.119.015009.
[19]

Gozdzik A, Marwick TH, Przewlocka-Kosmala M, et al. Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction[J/OL]. ESC Heart Fail, 2021, 8(2): 1531−1540[2023-02-13]. https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13247. DOI: 10.1002/ehf2.13247.
[20] Morris DA, Belyavskiy E, Aravind-Kumar R, et al.  Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction[J]. JACC Cardiovasc Imaging, 2018, 11(10): 1405-1415.   doi: 10.1016/j.jcmg.2017.07.029
[21] Vassiliou VS, Patel HC, Rosen SD, et al.  Left atrial dilation in patients with heart failure and preserved ejection fraction: insights from cardiovascular magnetic resonance[J]. Int J Cardiol, 2016, 210: 158-160.   doi: 10.1016/j.ijcard.2016.02.101
[22] Buss SJ, Krautz B, Schnackenburg B, et al.  Classification of diastolic function with phase-contrast cardiac magnetic resonance imaging: validation with echocardiography and age-related reference values[J]. Clin Res Cardiol, 2014, 103(6): 441-450.   doi: 10.1007/s00392-014-0669-3
[23] Backhaus SJ, Lange T, George EF, et al.  Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-stress trial[J]. Circulation, 2021, 143(15): 1484-1498.   doi: 10.1161/CIRCULATIONAHA.120.051542
[24] Rankin AJ, Zhu LK, Mangion K, et al.  Global longitudinal strain by feature-tracking cardiovascular magnetic resonance imaging predicts mortality in patients with end-stage kidney disease[J]. Clin Kidney J, 2021, 14(10): 2187-2196.   doi: 10.1093/ckj/sfab020
[25] Pieske B, Tschöpe C, de Boer RA, et al.  How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2019, 40(40): 3297-3317.   doi: 10.1093/eurheartj/ehz641
[26] Kato S, Saito N, Kirigaya H, et al.  Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction[J]. Int J Cardiol, 2015, 191: 314-319.   doi: 10.1016/j.ijcard.2015.05.048
[27] Mordi IR, Singh S, Rudd A, et al.  Comprehensive echocardiographic and cardiac magnetic resonance evaluation differentiates among heart failure with preserved ejection fraction patients, hypertensive patients, and healthy control subjects[J]. JACC Cardiovasc Imaging, 2018, 11(4): 577-585.   doi: 10.1016/j.jcmg.2017.05.022
[28] Roy C, Slimani A, de Meester C, et al.  Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction[J]. J Cardiovasc Magn Reson, 2018, 20(1): 55-.   doi: 10.1186/s12968-018-0477-4
[29]

Kanagala P, Cheng ASH, Singh A, et al. Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction[J]. JACC Cardiovasc Imaging, 2019, 12(11 Pt 2): 2291−2301. DOI: 10.1016/j.jcmg.2018.11.031.
[30] deKemp RA, Renaud JM, Klein R, et al.  Radionuclide tracers for myocardial perfusion imaging and blood flow quantification[J]. Cardiol Clin, 2016, 34(1): 37-46.   doi: 10.1016/j.ccl.2015.08.001
[31] Srivaratharajah K, Coutinho T, deKemp R, et al.  Reduced myocardial flow in heart failure patients with preserved ejection fraction[J]. Circ Heart Fail, 2016, 9(7): e002562-.   doi: 10.1161/CIRCHEARTFAILURE.115.002562
[32] Taqueti VR, Solomon SD, Shah AM, et al.  Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction[J]. Eur Heart J, 2018, 39(10): 840-849.   doi: 10.1093/eurheartj/ehx721
[33] Bennani Smires Y, Victor G, Ribes D, et al.  Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy[J]. Int J Cardiovasc Imaging, 2016, 32(9): 1403-1413.   doi: 10.1007/s10554-016-0915-z
[34] Hahn VS, Yanek LR, Vaishnav J, et al.  Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis[J]. JACC Heart Fail, 2020, 8(9): 712-724.   doi: 10.1016/j.jchf.2020.04.007
[35]

Brownrigg J, Lorenzini M, Lumley M, et al. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis[J/OL]. ESC Heart Fail, 2019, 6(5): 1041−1051 [2023-02-13]. https://onlinelibrary.wiley.com/doi/10.1002/ehf2.12511. DOI: 10.1002/ehf2.12511.
[36] Cuddy SAM, Bravo PE, Falk RH, et al.  Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?[J]. JACC Cardiovasc Imaging, 2020, 13(6): 1325-1336.   doi: 10.1016/j.jcmg.2020.02.025
[37] Aikawa T, Naya M, Obara M, et al.  Impaired myocardial sympathetic innervation is associated with diastolic dysfunction in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study[J]. J Nucl Med, 2017, 58(5): 784-790.   doi: 10.2967/jnumed.116.178558
[38] Bateman TM, Ananthasubramaniam K, Berman DS, et al.  Reliability of the 123I-mIBG heart/mediastinum ratio: results of a multicenter test-retest reproducibility study[J]. J Nucl Cardiol, 2019, 26(5): 1555-1565.   doi: 10.1007/s12350-017-1183-6
[39] Jacobson AF, Senior R, Cerqueira MD, et al.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study[J]. J Am Coll Cardiol, 2010, 55(20): 2212-2221.   doi: 10.1016/j.jacc.2010.01.014
[40]

Kiuchi MG, Nolde JM, Villacorta H, et al. New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system[J/OL]. Int J Mol Sci, 2019, 20(10): 2430[2023-02-13]. https://www.mdpi.com/1422-0067/20/10/2430. DOI: 10.3390/ijms20102430.
[41] Seo M, Yamada T, Tamaki S, et al.  Prognostic significance of cardiac 123I-MIBG SPECT imaging in heart failure patients with preserved ejection fraction[J]. JACC Cardiovasc Imaging, 2022, 15(4): 655-668.   doi: 10.1016/j.jcmg.2021.08.003
[42] Hashimoto H, Nakanishi R, Mizumura S, et al.  Prognostic values of 123I-MIBG myocardial scintigraphy and heart rate variability in patients with heart failure with preserved ejection fraction[J]. J Nucl Cardiol, 2020, 27(3): 833-842.   doi: 10.1007/s12350-018-01494-x
[43] Thackeray JT, Bengel FM.  Assessment of cardiac autonomic neuronal function using PET imaging[J]. J Nucl Cardiol, 2013, 20(1): 150-165.   doi: 10.1007/s12350-012-9644-4
[44] de Haan S, Rijnierse MT, Harms HJ, et al.  Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: a PET and CMR study[J]. J Nucl Cardiol, 2016, 23(6): 1480-1488.   doi: 10.1007/s12350-015-0316-z
[45] Lautamaki R, Sasano T, Higuchi T, et al.  Multiparametric molecular imaging provides mechanistic insights into sympathetic innervation impairment in the viable infarct border zone[J]. J Nucl Med, 2015, 56(3): 457-463.   doi: 10.2967/jnumed.114.149971
[46] Zelt JGE, Britt D, Mair BA, et al.  Regional distribution of fluorine-18-flubrobenguane and carbon-11-hydroxyephedrine for cardiac PET imaging of sympathetic innervation[J]. JACC Cardiovasc Imaging, 2021, 14(7): 1425-1436.   doi: 10.1016/j.jcmg.2020.09.026
[47] Cardoso R, Leucker TM.  Applications of PET-MR imaging in cardiovascular disorders[J]. PET Clin, 2020, 15(4): 509-520.   doi: 10.1016/j.cpet.2020.06.007